Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 731 participants.
Also called NCT03021187
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 731 participants
- Sponsor
- Registry
-
NCT03021187 -
2016-000988-16
-
- Main results
- Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, France, Greece, India, Japan, Mexico, Poland, Puerto Rico, Russia
- Registry status
- Completed
Technical summary
Registry record NCT03021187. Randomized; double masking; primary purpose treatment. Start 2017-02-02 (actual); primary completion 2018-01-18 (actual). Results posted on 2019-11-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
- Acronym
- PIONEER 8
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03021187- Content hash
0df47ca2450abdcef30f1b0cbec06c1aa24cd25066c8159422ac32456d78674d